Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology (VHIO) has been appointed chairman of the European consortium Cancer Core Europe. A project that was founded in 2014 to accelerate the development of innovative cancer therapies through close collaboration in clinical research
What is Cancer Core Europe (CCE)?
Cancer Core Europe (CCE) is a unique partnership aimed at addressing the cancer care–cancer research continuum challenge. In comments about his new position as board chairman, Josep Tabernero stated his eagerness to take on the challenge: “I really appreciate this opportunity to lead this project in which VHIO has been participating with a prominent role since its inception. I am grateful for the trust to keep on working to improve cancer care and research in Europe.”
VHIO is one of the six founding partners of the Cancer Core Europe consortium together with the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), the Cambridge Cancer Center (Cambridge, United Kingdom), the Karolinska Institute (Stockholm, Sweden), the Institute Netherlands Cancer Institute (NKI, Amsterdam, Netherlands), the National Center for Tumor Diseases (DKFZ-NCT, Heidelberg, Germany), and the National Cancer Institute in Milan, Italy. All of them, comprehensive centers of excellence for cancer treatment.
Cancer Core Europe promotes the pooling and exchange of expertise, research findings, common platforms and processes, and empowers researchers and clinicians to rapidly exploit this trove of biological insights and clinical data for the benefit of patients.
About Dr. Josep Tabernero
Dr. Tabernero is Head of the Department of Medical Oncology at Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO), and Professor of Medicine at UVic-UCC. He has been the principal investigator of several phase I pharmacodynamic studies and translational projects with tumor-targeted therapies and immune-based therapies.
Dr. Tabernero is on the editorial boards of various leading journals, such as Annals of Oncology, ESMO Open, and Cancer Discovery, among others. He has been part of the CCE Board of Directors since 2014, was president (2018–2019) of the European Society for Medical Oncology (ESMO), and is also part of the Public Policy and Antineoplastic Drugs commissions.
To learn more about Cancer Core Europe, please visit www.cancercoreeurope.eu
